Biology and treatment progress of KRAS-mutant non-small cell lung cancer
10.3760/cma.j.cn115355-20200909-00514
- VernacularTitle:KRAS突变非小细胞肺癌的生物学和治疗研究进展
- Author:
Jingying NONG
;
Xiaoxue LI
;
Shuyang YAO
;
Yi ZHANG
- From:
Cancer Research and Clinic
2021;33(1):69-73
- CountryChina
- Language:Chinese
-
Abstract:
KRAS mutation is one of the most frequent driver gene mutations found in patients with non-small cell lung cancer (NSCLC). KRAS-mutant NSCLC is highly heterogeneous. Various mutation types and different co-mutational signatures affect tumor biological behavior and therapeutic responses. NSCLC patients with KRAS mutations could relatively benefit from immunotherapy, while the effects of KRAS mutations on chemotherapy are still controversial. The treatment methods of KRAS-mutant lung cancer have followed the therapy of NSCLC without driver gene mutation for a long time. With the introduction of novel KRAS G12C inhibitors in the clinic, the therapeutic landscape has begun to change and has made the preliminary advance, and the combined therapies resulted in encouraging signals of efficacy both in preclinical and early phase trials. This paper reviews the biological and clinical characteristics as well as the latest treatment progress of KRAS-mutant NSCLC.
